The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae
Open accessAbstract
We studied outcomes of extended-spectrum β-lactamase (ESBL) production in Enterobacteriaceae bacteremia. Inpatients with bacteremia caused by ESBL-producing Escherichia coli , Klebsiella spp., or Proteus spp. (cases) were compared with patients with bacteremia caused by non-ESBL producers (controls). Outcomes included mortality, mortality due to infection, length of stay (LOS), delay in appropriate therapy (DAT), discharge to a chronic care facility, and hospital cost. Ninety-nine cases and 99 controls were enrolled. Thirty-five percent of cases died, versus 18% of controls (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.3 to 4.7; P = 0.01). Thirty percent of cases died due to infection, versus 16% of controls (OR, 2.3; 95% CI, 1.1 to 4.5; P = 0.03). The median LOS after bacteremia for cases was 11 days (interquartile range, 5 to 21), versus 5 days for controls (interquartile range, 3 to 9) ( P < 0.001). DAT occurred in 66% of cases, versus 7% of controls (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001). Cases were more likely than controls to be discharged to chronic care (52% versus 21%; OR, 4.0; 95% CI, 1.9 to 8.3; P < 0.001). The average hospital cost for cases was 65,509 Israeli shekels, versus 23,538 shekels for controls ( P < 0.001). After adjusting for differences between groups by using multivariable analysis, ESBL production remained a significant predictor of mortality (OR, 3.6; 95% CI, 1.4 to 9.5; P = 0.008), increased LOS (1.56-fold; P = 0.001), DAT (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001), and increased cost (1.57-fold; P = 0.003). The mean increase in equivalent cost attributable to ESBL production was $9,620. ESBL production was associated with severe adverse outcomes, including higher overall and infection-related mortality, increased LOS, DAT, discharge to chronic care, and higher costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,618
Gram-Negative Bacteremia: I. Etiology and Ecology
McCABE, W. R. (1962) · Archives of Internal Medicine · doi:10.1001/archinte.1962.03620240029006 · Cited by 1,362
Kreger, B. E., Craven, D. E., & McCabe, W. R. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90102-3 · Cited by 1,314
Knothe, H., Shah, P., Krcmery, V., Antal, M., & Mitsuhashi, S. (1983) · Infection · doi:10.1007/bf01641355 · Cited by 912
Lautenbach, E., Patel, J. B., Bilker, W. B., Edelstein, P. H., & Fishman, N. O. (2001) · Clinical Infectious Diseases · doi:10.1086/319757 · Cited by 747
The Impact of Antimicrobial Resistance on Health and Economic Outcomes
Eliopoulos, G. M., Cosgrove, S. E., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/375081 · Cited by 637
Self-citationPaterson, D. L., Ko, W.-C., Gottberg, A. V., Mohapatra, S., Casellas, J. M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K. P., Bonomo, R. A., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-1-200401060-00008 · Cited by 631
Eliopoulos, G. M., & Bush, K. (2001) · Clinical Infectious Diseases · doi:10.1086/319610 · Cited by 392
Health and Economic Outcomes of Antibiotic Resistance in Pseudomonas aeruginosa
Carmeli, Y., Troillet, N., Karchmer, A. W., & Samore, M. H. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.10.1127 · Cited by 363
Self-citationKim, Y.-K., Pai, H., Lee, H.-J., Park, S.-E., Choi, E.-H., Kim, J., Kim, J.-H., & Kim, E.-C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1481-1491.2002 · Cited by 357
Cited by
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Mathers, A. J., Peirano, G., & Pitout, J. D. D. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00116-14 · Cited by 872
Schwaber, M. J., & Carmeli, Y. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm318 · Cited by 626
Self-citationSchwaber, M. J., Klarfeld-Lidji, S., Navon-Venezia, S., Schwartz, D., Leavitt, A., & Carmeli, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-07 · Cited by 483
Self-citationTumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E. M., Posteraro, B., Fiori, B., Citton, R., D'Inzeo, T., Fadda, G., Cauda, R., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01509-06 · Cited by 461
Metadata
- Authors
- Schwaber, M. J., Navon-Venezia, S., Kaye, K. S., Ben-Ami, R., Schwartz, D., & Carmeli, Y.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-04
- Volume
- 50
- Issue
- 4
- Pages
- 1257-1262
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2128956519
- Cited by
- 416
- References
- 18
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae. https://app.cochat.ai/papers/10.1128/aac.50.4.1257-1262.2006
- The paper
- Schwaber, M. J., Navon-Venezia, S., Kaye, K. S., Ben-Ami, R., Schwartz, D., & Carmeli, Y. (2006). Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.50.4.1257-1262.2006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.